These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 4761443)
1. [Spasmolytic and mucolytic agents in the treatment of acute dyspneic pneumopathies in children]. Manicatide ET; Căpraru H Pediatria (Bucur); 1973; 22(4):357-60. PubMed ID: 4761443 [No Abstract] [Full Text] [Related]
3. [Treatment of spastic bronchitis with a new bronchospasmolytic agent]. Heller K Wien Med Wochenschr; 1972 Oct; 122(42):606-9. PubMed ID: 5081450 [No Abstract] [Full Text] [Related]
4. [Experience with Baby-Liberol, a percutaneous expectorant, in infants and small children]. Hanker H Z Allgemeinmed; 1969 Feb; 45(6):268-9. PubMed ID: 5801647 [No Abstract] [Full Text] [Related]
5. [Report on experience with a percutaneous expectorant]. Post E Landarzt; 1967 Nov; 43(32):1594-5. PubMed ID: 5594630 [No Abstract] [Full Text] [Related]
6. [Secretolysis through gelomyrtol]. Kurz JF Z Allgemeinmed; 1970 Nov; 46(32):1623-7. PubMed ID: 4934657 [No Abstract] [Full Text] [Related]
7. [Comparison of the bronchodilator action of salbutamol and orciprenaline by aerosol administration in patients with chronic bronchopneumopathy]. Sorbini CA; Todisco T; Boschetti E Minerva Med; 1976 Mar; 67(16):1079-83. PubMed ID: 1264384 [No Abstract] [Full Text] [Related]
8. [Clinical experiences with a new beta 2-receptor stimulant in spastic lung diseases in pediatrics]. Starnegg Q Wien Med Wochenschr; 1971 May; 121(22):455-7. PubMed ID: 5092121 [No Abstract] [Full Text] [Related]
9. [Clinical experiences with a new bronchospasmolytic agent in infancy and childhood]. Nachtigall C Med Monatsschr; 1968 Dec; 22(12):555-7. PubMed ID: 5709425 [No Abstract] [Full Text] [Related]
10. [Advantages of mucolytic treatment in bronchitis and bronchial asthma in children]. Hadydoń B; Chalon Z; Gruszecki J Pediatr Pol; 1966 Oct; 41(10):1177-80. PubMed ID: 5977179 [No Abstract] [Full Text] [Related]
11. [Recommendations for a stepwise plan of long-term drug therapy in obstructive airway diseases]. Geisler LS Dtsch Med Wochenschr; 1988 Oct; 113(41):1609-12. PubMed ID: 2901943 [No Abstract] [Full Text] [Related]
12. [Effectiveness of aerosol treatment with spasmolytic agents of obstructive bronchitis in infancy and early childhood]. Tatotschenko WK; Schirjajewa IS; Tarasenko TD; Batyrchanow SK; Reutowa WS; Dorochowa NP; Krolik EB Z Erkr Atmungsorgane; 1988; 171(2):168-74. PubMed ID: 2977027 [TBL] [Abstract][Full Text] [Related]
13. [Inhalation therapy at the bed-side. Surgical and anesthesiological problems]. Rügheimer E; Grimm H Med Klin; 1971 Jun; 66(26):955-9. PubMed ID: 5089352 [No Abstract] [Full Text] [Related]
14. Is there a selective indication for a parasympatholytic (Atrovent) and for a beta-sympathomimetic (Berotec) in asthma and asthmatic bronchitis? Verstraeten JM Acta Tuberc Pneumol Belg; 1976; 67(3-4):130-55. PubMed ID: 138352 [No Abstract] [Full Text] [Related]
15. [On the value and effectiveness of the use of an association of an isoproterenol derivative and calcium iodide in respiratory tract diseases in the aged]. Barbieri R; Michetti A Minerva Med; 1971 May; 62(36):1858-69. PubMed ID: 5580497 [No Abstract] [Full Text] [Related]
16. [Bronchospasmolytic and extrabronchial action of Berotec (Fenoterol, Th 1165) in patients with asthma or chronic bronchitis with bronchial spasm]. Rozniecki J; Grabski W Pol Tyg Lek; 1975 Feb; 30(7):301-4. PubMed ID: 1118349 [No Abstract] [Full Text] [Related]